This article has been accepted for publication and undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process, which may lead to differences between this version and the Version of Record. Please cite this article as doi: 10.1111/cea.12065
1365-2222/asset/cea_left.gif?v=1&s=676c5dd6c41538d1202eb686abd82748c570d4d8)
1365-2222/asset/cea_centre.gif?v=1&s=4761aeed79a4957313f41ba37276a359d407e600)
1365-2222/asset/cea_right.gif?v=1&s=f089a0803409931b9630fc86f2f8b0dc887deb4b)
Invited Review
Role of CCL18 in asthma and lung immunity
DOI: 10.1111/cea.12065
© 2012 Blackwell Publishing Ltd
Issue
Additional Information
Publication History
- Accepted manuscript online: 26 NOV 2012 04:43AM EST
- Manuscript Accepted: 1 NOV 2012
- Manuscript Revised: 29 OCT 2012
- Manuscript Received: 18 SEP 2012
- Abstract
- Cited By
Summary
Allergic asthma is a prototypic Th2 mediated disease, where chemokines orchestrate the inflammatory cell recruitment. Most chemokines have a pro inflammatory role. In the present review, we focus on the potential role, in asthma and lung immunity, of CCL18 a chemokine both constitutively expressed at high levels in the lung and induced in inflammatory conditions. This chemokine is mainly produced by antigen-presenting cells, and induced by Th2 type cytokines. The available data suggest that this chemokine may exhibit dual functions, with both pro- and anti-inflammatory properties, the latter through its ability to generate adaptive regulatory T cells in healthy subjects, with a loss of function in allergic patients. However, the functional implications are at the moment hampered by the lack of data on the nature of its putative receptor, and the absence of murine orthologue.
© 2012 Blackwell Publishing Ltd